Skip to Content
Merck
All Photos(1)

Key Documents

A7856

Sigma-Aldrich

Acipimox

≥99% (TLC)

Synonym(s):

2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C6H6N2O3
CAS Number:
Molecular Weight:
154.12
EC Number:
UNSPSC Code:
12352205
NACRES:
NA.79

Assay

≥99% (TLC)

form

powder

color

off-white to faint yellow

mp

177-180 °C

storage temp.

2-8°C

InChI

1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)

InChI key

DNRXJHATQULEHC-UHFFFAOYSA-N

Biochem/physiol Actions

Acipimox, also known as olbemox, is a nicotinic acid analog. It functions as an anti-lipolytic drug and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin. It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.
Niacin-derived, vasodilator studied for its lipid-lowering effect.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mads Halbirk et al.
American journal of physiology. Heart and circulatory physiology, 299(4), H1220-H1225 (2010-08-17)
Circulating free fatty acids (FFAs) may worsen heart failure (HF) due to myocardial lipotoxicity and impaired energy generation. We studied cardiac and whole body effects of 28 days of suppression of circulating FFAs with acipimox in patients with chronic HF.
Fabrizio Montecucco et al.
American journal of physiology. Endocrinology and metabolism, 300(4), E681-E690 (2011-01-27)
Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on
Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
Cordido F, et al.
The Journal of clinical endocrinology and metabolism, 81(3), 914-918 (1996)
Hanna-Riikka Lehto et al.
The Journal of clinical endocrinology and metabolism, 97(9), 3277-3284 (2012-07-05)
We tested the hypothesis that a persistent reduction in free fatty acid (FFA) levels improves cardiac function and systemic insulin sensitivity via a reduction in the myocardial and skeletal muscle adiposities and a modulation in adipokine release. Study subjects (body
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia
Taskinen MR and Nikkila EA
Atherosclerosis, 69(2-3), 249-255 (1988)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service